Can molotinib/mometinib be purchased in China? when

Momelotinib is a treatment drug for myelofibrosis (MF) and is a small molecule tyrosine kinase inhibitor. This drug mainly regulates signaling pathways related to hematopoiesis and immune response by inhibiting two key tyrosine kinases, JAK1 and JAK2. Myelofibrosis is a rare blood disease. Patients are often accompanied by splenomegaly, anemia, and systemic symptoms such as fatigue and weight loss. These symptoms seriously affect the patient's quality of life.

The main effect of molotinib is to improve the patient's symptoms, especially in reducing splenomegaly. At the same time, it also helps improve anemia problems associated with myelofibrosis. Studies have shown that molotinib not only effectively reduces spleen enlargement, but also reduces dependence on blood transfusions and improves patients' overall health and quality of life. This makes it unique in the treatment of myelofibrosis, especially in patients who are ineffective or resistant to other treatments.

Currently, molotinib is undergoing clinical trials in many countries and regions and has been approved in some places. Although the drug has received widespread attention internationally, the situation in the Chinese market is relatively complicated. Currently, the original drug of molotinib has not yet been launched in China, so patients cannot purchase the drug through formal channels. As it is still in the clinical research stage, the relevant approval procedures and market entry strategies are still in progress.

Although molotinib has not yet been launched in China, China's medical market has gradually increased demand for new therapeutic drugs, especially for the treatment of rare diseases. With the deepening of research and the announcement of clinical trial results, molotinib may be approved by the Chinese Food and Drug Administration in the future, thereby providing a new treatment option for domestic myelofibrosis patients.

References:https://www.gsk.com/en-gb/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/